Detalhe da pesquisa
1.
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Leukemia;
33(4): 905-917, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30214012